Algorae PharmaceuticalsASX:1AI +10.00% Market Cap is A$20.26 Mil as of Jun. 25, 2026. The stock has 2 warning signs investors should review. Among 1,431 Biotechnology companies, Algorae Pharmaceuticals ranks worse than 80.71% on this metric.
Algorae Pharmaceuticals's quarterly market cap
declined
from Dec. 2024 (A$10.12 Mil) to Jun. 2025 (A$8.44 Mil) but then
increased
from Jun. 2025 (A$8.44 Mil) to Dec. 2025 (A$23.64 Mil).
Algorae Pharmaceuticals's annual market cap
declined
from Jun. 2023 (A$23.40 Mil) to Jun. 2024 (A$16.87 Mil) and
declined
from Jun. 2024 (A$16.87 Mil) to Jun. 2025 (A$8.44 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Algorae Pharmaceuticals's Enterprise Value for Today is A$18.37 Mil.
Algorae Pharmaceuticals (ASX:1AI) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Algorae Pharmaceuticals Market Cap Related Terms
Algorae Pharmaceuticals Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:1AI vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Algorae Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Algorae Pharmaceuticals Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Algorae Pharmaceuticals's Market Cap distribution charts can be found below:
* The bar in red indicates where Algorae Pharmaceuticals's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Algorae Pharmaceuticals's Market Cap for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Algorae Pharmaceuticals (ASX:1AI) has a Market Cap of A$20.26 Mil as of Jun. 25, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Algorae Pharmaceuticals and its competitors. According to the industry distribution chart, Algorae Pharmaceuticals ranks #1155 out of 1431 companies in the Biotechnology industry, placing it in the top 80.7%.
Is Algorae Pharmaceuticals' Market Cap too high?
Algorae Pharmaceuticals' current Market Cap is A$20.26 Mil. Based on the distribution chart, Algorae Pharmaceuticals ranks #1155 out of 1431 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Algorae Pharmaceuticals' Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Algorae Pharmaceuticals ranks #1155 out of 1431 companies for Market Cap. This places Algorae Pharmaceuticals in the lower half of its industry. The industry median Market Cap is 117.63. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 117.63, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Algorae Pharmaceuticals and its competitors. For the Biotechnology industry, the median Market Cap is 117.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Algorae Pharmaceuticals's current Market Cap is A$20.26 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Algorae Pharmaceuticals stock overvalued right now?
Algorae Pharmaceuticals (ASX:1AI) has a current Market Cap of A$20.26 Mil. The current Market Cap is A$20.26 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Algorae Pharmaceuticals (ASX:1AI), the current Market Cap is A$20.26 Mil as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Algorae Pharmaceuticals Ltd is a clinical-stage pharmaceutical company developing transformative solutions for under met medical needs in the community. The firm develops AlgoraeOS, a closed-loop platform, leveraging computational tools to generate novel insights in silico that are being developed to initiate or accelerate therapeutic programs. The products of the company comprise AI-116, a novel combination drug candidate of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. The company is conceptualized to be a potential treatment for dementia, including Alzheimer's disease, NTCELL is an alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells. It also offers LP-003 Anti-obesity Drug and LC-002 migraine treatment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:1AI has been successfully added to your 